Company Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 14/09/2024 am IST			5-day change	1st Jan Change
116.00 ^USD	+1.64%		+3.96%	+84.71%

10/09	Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...
10/09	Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	MT

Business description: Vaxcyte, Inc.

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Number of employees: 254

Sales by Activity: Vaxcyte, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023

See all business segments

Geographical breakdown of sales: Vaxcyte, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023

See all geographic segments

Managers: Vaxcyte, Inc.

Director	Title	Age	Since
Jeff Fairman FOU	Founder	60	27/13/27
Grant Pickering FOU	Founder	56	27/13/27
Andrew Guggenhime DFI	Director of Finance/CFO	55	01/20/01
Jakub Simon CTO	Chief Tech/Sci/R&D Officer	-	11/22/11
Mikhail Eydelman CMP	Compliance Officer	43	01/22/01

See VAXCYTE, INC. governance

Members of the board: Vaxcyte, Inc.

Manager	Title	Age	Since
Grant Pickering FOU	Founder	56	27/13/27
K. Hirth BRD	Director/Board Member	72	01/16/01
Heath Lukatch BRD	Director/Board Member	56	01/18/01
Halley Gilbert BRD	Director/Board Member	54	01/20/01
Teri Loxam BRD	Director/Board Member	52	16/21/16
Anne Drapeau BRD	Director/Board Member	57	16/21/16
Carlos Paya CHM	Chairman	65	27/21/27
Jacks Lee BRD	Director/Board Member	60	27/11
John Furey BRD	Director/Board Member	59	02/07

Composition of the Board of Directors

Shareholders: Vaxcyte, Inc.

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 14.49 %	16,167,340	14.49 %	1 306 M $
Vanguard Fiduciary Trust Co. 8.778 %	9,796,995	8.778 %	791 M $
BlackRock Advisors LLC 8.235 %	9,191,343	8.235 %	742 M $
Janus Henderson Investors US LLC 7.946 %	8,868,907	7.946 %	716 M $
RA Capital Management LP 7.350 %	8,203,754	7.350 %	663 M $

List of VAXCYTE, INC. shareholders

Company details: Vaxcyte, Inc.

Vaxcyte, Inc.

825 Industrial Road Suite 300

94070, San Carlos

+650 837 0111

http://www.vaxcyte.com

Bio Therapeutic Drugs

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
VAXCYTE, INC.	+1.64%	+3.96%	+125.24%	+347.53%	1.43TCr
VERTEX PHARMACEUTICALS INCORPORATED	+1.40%	+3.71%	+38.91%	+157.61%	13TCr
REGENERON PHARMACEUTICALS, INC.	-0.95%	+1.93%	+38.56%	+78.77%	12TCr
ARGENX SE	+0.41%	+0.08%	-0.57%	+76.56%	3.24TCr
BIONTECH SE	+17.52%	+37.20%	+8.43%	-63.15%	2.93TCr
SUMMIT THERAPEUTICS INC.	+16.49%	+160.23%	+1,571.73%	+398.91%	2.31TCr
BEIGENE, LTD.	+1.13%	+3.75%	-0.01%	-46.19%	2.11TCr
GENMAB A/S	+1.18%	-3.23%	-33.58%	-35.25%	1.7TCr
WUXI APPTEC CO., LTD.	+0.15%	+2.63%	-48.92%	-71.95%	1.6TCr
INSMED INCORPORATED	+1.01%	+5.10%	+179.94%	+173.48%	1.28TCr
Average	+4.00%	+21.30%	+187.97%	+101.63%	4.16TCr
Weighted average by Cap.	+2.52%	+13.42%	+117.87%	+105.54%